Navigation Links
FDA Clears Sysmex XE-2100D Hematology Analyzer for Blood Processing Center Quality Control Release Testing
Date:9/22/2009

MUNDELEIN, Ill., Sept. 22 /PRNewswire/ -- Sysmex, a global leader in medical diagnostic testing equipment and information systems technology, today announced that its Sysmex XE-2100D Automated Hematology Analyzer has been cleared by the United States Food and Drug Administration (FDA) for blood processing center Quality Control release testing of post-processed red blood cell and platelet components collected using a variety of anticoagulants. Historically, the Sysmex XE-2100D had been cleared for in vitro diagnostic use in clinical laboratories and donor centers as a multi-parameter hematology analyzer for whole blood samples using EDTA anticoagulant. Sysmex is the only original equipment manufacturer to receive FDA cleared anticoagulant Intended Use claims for the Blood Center/Blood Bank market that addresses Quality Control needs, said John Kershaw, CEO, Sysmex America, Inc.

"The nation's blood centers play a critical role in servicing the blood transfusion needs of hospitals across the country. As a best-in-class hematology instrument provider, Sysmex continued development based on blood center customer input. We invested the time and money necessary to conduct the extensive studies required by the FDA to achieve this clearance milestone. The ability to use the XE-2100D with these anticoagulants enables blood centers to meet the FDA's rigorous manufacturing classification demands. It streamlines the validation and documentation process necessary to meet those requirements, providing the potential for improving efficiency and labor utilization," said Kershaw.

Since blood centers are classified as manufacturing organizations, they are highly regulated by the FDA. All instruments and products are to be used according to the manufacturer's intended use and instructions. Any deviation from any of the manufacturers' intended use statements requires extensive validation and docu
'/>"/>

SOURCE Sysmex America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Global Gene Map Clears New Milestone
2. FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software
3. American Medical Association Clears Path for Adenoviral Conjunctivitis - Pink Eye - Detector
4. Congress Clears the Way for National CPR and AED Awareness Week
5. FDA Clears Cellsearch(TM) Circulating Tumor Cell Test for Monitoring Metastatic Prostate Cancer Patients
6. ClearScript Offers Innovative Medication Therapy Management Program to Employee Health Plans
7. Alzheimers vaccine clears plaque but has little effect on learning and memory impairment
8. Genetic Information Nondiscrimination Act clears Senate
9. Dutch Authorize Manufacture of Vaccinogens New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial
10. FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression
11. FDA Clears the DPL (Deep Penetrating Light) Therapy System for Over-the-Counter - Home Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... Medicine researchers have been awarded two-year grants for their ... this month. Of the 110 initial submissions to the ... Program, only four projects were funded, three of which ... Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias ... of oncology, will use his $500,000 proof of principle ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... researchers will lead a $10.25 million effort to study ... need for dialysis. The five-year project supports research ... that, though rare, generates an enormous individual and societal ... to nearly 12 percent of cases of kidney failure, ...
... , , , ... by wearing a purple LFA wristband until there is an FDA-approved medication ... It,s been 50 years since the U.S. Food and Drug Administration (FDA) ... President! To highlight the need for safer, more tolerable, and effective medications, ...
... NEW YORK, Sept. 22 The Global Network ... partnership with the Miss Universe Organization aimed at educating millions ... control and eliminate neglected tropical diseases across the region. ... time in their home countries participating in education and mass ...
... , , SAN MARCOS, Calif., ... NAII ), a leading formulator, manufacturer and marketer of customized nutritional ... per diluted share on net sales from continuing operations of $73.9 ... fiscal 2009 results include a net loss from discontinued operations of ...
... , , NEW YORK, Sept. 22 ... of specialty insurance and insurance-related products and services, will release 2009 third ... The news release will be available on Assurant,s Web site at ... broadcast its 2009 third quarter conference call at 9:00 a.m. ET on ...
... ELM GROVE, Wis., Sept. 22 A free ... Factor in HAI , is being sponsored by Compirion Healthcare Solutions, ... Wisconsin. Dates and times, along with registration information, can be found ... webinar are the main causes of non-compliance with hospital hand-washing ...
Cached Medicine News:Health News:Kidney advocates launch $10.25 million effort to examine cause of kidney failure 2Health News:The Lupus Foundation of America, Inc. Asks Supporters to Band Together for Lupus(SM) 2Health News:Miss Universe Organization, Global Network for Neglected Tropical Diseases Join Forces to Eliminate Neglected Tropical Diseases in the Americas 2Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 2Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 3Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 4Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 5Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 6Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 7Health News:Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results 8Health News:Assurant to Announce 2009 Third Quarter Results Oct. 28, 2009 and Host Webcast Conference Call Oct. 29 2Health News:Free Webinar on Helping Hospitals Control Healthcare-Associated Infections by Improving Hand Hygiene 2Health News:Free Webinar on Helping Hospitals Control Healthcare-Associated Infections by Improving Hand Hygiene 3
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
(Date:1/14/2014)...   Oligomerix, Inc. , a privately held company pioneering ... (AD) and related neurodegenerative disorders, announced today the relocation ... as of January 15, 2014 and expanded ... Medical College. Oligomerix, which is focused on ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Inc. today announced that the U.S. Food and Drug ... (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment ... by any diagnosed conditions of the uterus (womb), in ... With this approval, Natazia is the first and only ...
... March 14, 2012  Nile Therapeutics, Inc. (OTCQB: NLTX), ... heart failure patients, today announced the schedule of ... American College of Cardiology (ACC) 61th Scientific Session, ... Monday, March 26, 2012 Time: 10:00 AM -12:00 PM ...
Cached Medicine Technology:U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 2U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 3U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 4Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting 2